Markus Renschler
Chief Executive Officer chez CYTEIR THERAPEUTICS, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Markus F.
Renschler is currently the President, Chief Executive Officer & Director at Cyteir Therapeutics, Inc. He previously held positions as the Senior Vice President & Global Head-Hematology at Celgene Corp., Senior VP-Oncology Clinical Development at Pharmacyclics LLC from 1996 to 2007, Vice President-Clinical Development at Pharmion Corp.
from 2007 to 2008, and Chief Medical Officer & Senior Vice President at Celgene Cellular Therapeutics from 2008 to 2017.
He also served as an Associate Professor at Stanford University.
Dr. Renschler holds a doctorate degree from Stanford University and an undergraduate degree from Princeton University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 1 103 661 ( 3,07% ) | 3 M $ | 31/03/2024 |
Postes actifs de Markus Renschler
| Sociétés | Poste | Début |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Chief Executive Officer | 01/01/2018 |
Anciens postes connus de Markus Renschler
| Sociétés | Poste | Fin |
|---|---|---|
Celgene Cellular Therapeutics
 Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The private company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
| Stanford University | Corporate Officer/Principal | 01/01/2015 |
Pharmion Corp.
 Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Chief Tech/Sci/R&D Officer | 01/01/2008 |
| PHARMACYCLICS, INC. | Chief Tech/Sci/R&D Officer | 28/12/2007 |
| CELGENE | Chief Tech/Sci/R&D Officer | - |
Formation de Markus Renschler
| Stanford University | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The private company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Health Technology |
